key: cord-1002228-0b1290yj
authors: Choudhary, Narendra S.; Dhampalwar, Swapnil; Saraf, Neeraj; Soin, Arvinder S.
title: Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation
date: 2021-05-12
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.05.003
sha: 2f053a4605ff2d8e741d8bafeb59a50f01f82b48
doc_id: 1002228
cord_uid: 0b1290yj

Coronavirus disease 2019 (COVID-19) is associated with a significant morbidity and mortality in patients with cirrhosis. There is a significantly higher morbidity and mortality due to COVID-19 in patients with decompensated cirrhosis as compared to compensated cirrhosis, and in patients with cirrhosis as compared to non-cirrhotic chronic liver disease. The fear of COVID-19 before or after liver transplantation has lead to a significant reduction in liver transplantation numbers, and patients with decompensated cirrhosis remain at risk of wait list mortality. The studies in liver transplantation recipients show that risk of mortality due to COVID-19 is generally driven by higher age and comorbidities. The current review discusses available literature regarding outcomes of COVID-19 in patients with cirrhosis and outcomes in liver transplant recipients.

Abnormal liver function tests (LFT) are common in patients with patients with COVID-19 in absence of chronic liver disease. A systematic review by Ghoshal et al showed that 10.5%-53% of patients with COVID-19 had raised liver enzymes, although jaundice was uncommon as the total bilirubin was raised in only 5-18% patients. A reduction in serum albumin is also reported by several studies. Patients with more severe COVID-19 associated disease had liver function test abnormalities more often. 12 Izcovich et al conducted a systematic review of 207 studies and found several variables that provided prognostic information about severe disease and/or mortality. High blood aspartate aminotransferase (AST), decrease in albumin and high blood bilirubin are associated with severe disease. 13 Patients with abnormal

LFTs have a worse prognosis as compared to those with normal LFT. Wu et al also looked at prognosis of abnormal LFTs in a meta-analysis by 45 studies, 14 the pooled incidence of any abnormal liver biochemistry at admission was 27.2% and during hospitalization 36%. At admission, abnormal albumin was the most common finding (39.8%) followed by gamma-glutamyl transferase (35.8%), AST (21.8%), alanine transaminase (ALT) (20.4%), total bilirubin (8.8%) and alkaline phosphatase (4.7%).

During hospitalization, abnormal ALT, AST and total bilirubin were present in 38.4%, 28.1%, and 23.2% respectively. Severe and or critical patients and nonsurvivors had a higher incidence of abnormal liver biochemical indicators. It should be noted that abnormal LFTs might be related to drugs or secondary to ischemia (if present) in addition to direct effects of COVID-19. 14 Although patients with non-cirrhotic chronic liver disease (CLD) may not have a higher mortality, patients with non-alcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) may have more disease severity/mortality due to frequent association with diabetes, obesity and metabolic syndrome. 15, 16 J o u r n a l P r e -p r o o f It is important to understand that these studies mainly detect case fatality rate (diagnosed cases) and not infection fatality rate (as asymptomatic or mild cases may not get tested). A systematic review of 73 studies (n=24299) showed that 3% patients with COVID-19 were suffering from underlying CLD. The presence of CLD was significantly associated with more severe infection [pooled Odds ratio (OR)1.48] and overall mortality (pooled OR 1.78). Moreover, there was a non-significant trend for increased ICU and invasive mechanical ventilation requirement in patients with CLD. 2 In a multicentric United States study, the presence of CLD and NAFLD was independently associated with ICU stay and mechanical ventilation. The presence of cirrhosis was a significant predictor of mortality (aOR 12.5, 95% CI 2.16-72.5). 17 Patients with liver disease, in particular patients with NASH may have higher comorbidities then non-liver disease patients. Singh et al compared 250 patients with liver disease (NASH being the most common sitology) to 2530 non-liver disease patients in a multicentric study. The patients in liver disease group were older and had higher comorbidities, including hypertension in 68% and diabetes in 48%. The authors found that the patients with liver disease were at significantly increased risk for mortality (RR, 2.8; 95% CI, 1.9-4.0; P < .001) after 1:1 propensity score matching. 18 Ioannou et al identified 88,747 patients tested for COVID-19 in the Veterans Affairs national healthcare system. The following groups were studied: no cirrhosis-SARS-CoV-2 negative (C0-S0, n=75,315), no cirrhosis-SARS-CoV-2 positive (C0-S1, n=9826); cirrhosis-SARS-CoV-2 negative (C1-S0, n=3301); cirrhosis-SARS-CoV-2 positive (C1-S1, n=305). The 30-day mortality and ventilation rates were 5.2% and 3.6% in C1-S0, and 17.1% and 13.0% in to C1-S1. The patients with cirrhosis and a positive test for SARS-CoV-2 were more likely to undergo mechanical ventilation and mortality, risk being 4.1 times and 3.5 times respectively.

Higher age, decompensation and high model for end-stage liver disease (MELD) score were predictors of mortality in patients with cirrhosis and SARS-CoV-2.

Cirrhosis was associated with a 1.7 times increase in mortality in patients with SARS-CoV-2 infection. 19

The risk of mortality increases with increasing severity of liver disease as shown in Thirty-nine recipients (16%) were managed as outpatients, 84% were hospitalized.

Forty-nine patients (20.2%) died with respiratory failure as the major cause.

Following factors predicted mortality on multivariable analysis: age >70 (HR, 4.16; 95% CI, 1.78-9.73) and tacrolimus use (protective effect, HR, 0.55; 95% CI, 0.31-0.99). In a model excluding age, both diabetes and chronic kidney disease were significantly associated with mortality. 37 A prospective Spanish study of 111 LT recipients with COVID-19 infection showed 18% mortality in LT recipients, this mortality rate was lower than matched general population. Thirty-five patients (31.5%) had severe Covid-19. The use of mycophenolate at baseline was an independent predictor of severe Covid-19, this effect was not observed with calcineurin inhibitors or everolimus. 39 Another study by Webb et al also did not find a higher mortality in LT recipients with COVID-19; mortality in LT recipients was similar to matched population without liver transplantation. 40 The authors compared adult LT recipients with severe COVID-19 (n=151) from a multicenter database (18 countries) to matched patients (n=627). The mortality was 19% in transplant cohort versus 27% in control cohort, p=0.046. The authors found that increased age and comorbidities were related to mortality. 40 Rabiee et al compared 112 adult LT recipients with COVID-19 to age and sex matched 375 CLD with COVID-19. The mortality rate was 22.3% in LT recipients, 72.3% were hospitalized and 26.8% were admitted to the intensive care unit. A reduction in immunosuppression was not associated with ALI or mortality. The ALI was significantly associated with mortality (p=0.007; OR, 6.91) and ICU admission 

China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

COVID-19 patients: a systematic review and meta-analysis

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study

Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality

Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI)

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Early impact of COVID-19 on transplant center practices and policies in the United States

The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy

ELITA-ELTR COVID-19 Registry. Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19

Determining risk factors for mortality in liver transplant patients with COVID-19

COLD Consortium. Liver Injury in Liver Transplant Recipients With

COVID-19 in Liver Transplant Recipients: An Initial Experience From the US Epicenter

Groupe de Recherche Français en

Covid-19 in liver transplant recipients: the French SOT COVID registry

COVID-19 in an international European liver transplant recipient cohort

Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Outcomes of Coronavirus Disease 2019 in Living Donor Liver Transplant Recipients

COVID-19 in solid organ transplant recipients: A single-center case series from Spain

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

A Multicentric Experience on Living Donor Liver Transplantation in COVID-19 Hotspots in India

Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability

Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?

COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis

Figure 1: Mortality in COVID-19, data based on references 5,22 and table